Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer

Jin,Canhui; Wang,Aihong; Chen,Jianmin; Liu,Xiaomin; Wang,Gongping

doi:10.3892/etm.2012.651

Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer

Authors:
- Canhui Jin
- Aihong Wang
- Jianmin Chen
- Xiaomin Liu
- Gongping Wang
View Affiliations

Affiliations: The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: July 31, 2012 https://doi.org/10.3892/etm.2012.651
Pages: 633-639

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), signal transducer and activator of transcription-3 (STAT3) and vascular endothelial growth factor-C (VEGF-C) and their relationship with clinicopathological features and prognostic ability was determined using immunohistochemistry in 68 cases of colorectal cancer with follow-up data. Kaplan-Meier survival analysis was performed and the prognostic value was determined using univariate analysis. PTEN, STAT3 and VEGF-C expression was detected in 32.4, 60.3 and 63.2% of colorectal carcinoma cases and 90.0, 0 and 0% of normal colon samples, respectively. PTEN and STAT3 were correlated with pathological grade (p=0.011, p=0.001, respectively), but not with tumor size, lymph node metastasis or clinical stage. VEGF-C was correlated with lymph node metastasis (p=0.002), but not with tumor size, pathological grade or clinical stage. Expression of STAT3 and VEGF-C was negatively correlated with PTEN (r=-0.402, r=-0.320, respectively), whereas STAT3 and VEGF-C expression was positively correlated with PTEN (r=0.254). The 3- and 5-year survival rates of PTEN protein-positive patients (68.1 and 50.0%, respectively) were significantly higher than those of PTEN protein-negative patients (32.6 and 19.6%, respectively; p=0.008). The 3- and 5-year survival rates of STAT3‑positive (29.3 and 17.1%, respectively) were significantly lower than those of STAT3‑negative patients (66.7 and 48.1%, respectively; p=0.005). The 3- and 5‑year survival rates of VEGF-C‑positive patients (29.3 and 17.1%, respectively) were significantly lower than the rates of VEGF-C-negative patients (66.7 and 48.1%, respectively; p=0.003, p=0.004, respectively). Multivariate analysis revealed that VEGF-C expression was an independent prognostic factor. In conclusion, this study indicates that PTEN, STAT3 and VEGF-C expression are beneficial prognostic factors, which may aid in the accurate assessment of prognosis and guide clinical treatment of colorectal cancer patients.

View Figures

View References

1	Higa R: Colorectal cancer: epidemiology and primary profilaxis. Acta Gastroenterol Latinoam. 41:70–73. 2011.PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3	Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ and Kim TY: KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog. 49:353–362. 2010. View Article : Google Scholar : PubMed/NCBI
4	Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ and Belldegrun AS: Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 18:894–900. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, et al: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS. 117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
6	Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M and Saito Y: Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol. 77:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
7	Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA and Ghosh PM: Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 13:3860–3867. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK and Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59:1820–1824. 1999.PubMed/NCBI
9	Lee HS, Lee HK, Kim HS, Yang HK and Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 200:39–46. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zhang S and Yu D: PI(3)king apart PTEN’s role in cancer. Clin Cancer Res. 16:4325–4330. 2010.PubMed/NCBI
11	Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD and Goldspink G: The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. 555:231–240. 2004. View Article : Google Scholar : PubMed/NCBI
12	Couffinhal T, Dufourcq P and Duplàa C: Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? Circ Res. 99:1287–1289. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, Wang DH, Spechler SJ and Souza RF: Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells. Am J Physiol Gastrointest Liver Physiol. 300:G454–G460. 2011.
14	Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 58:833–838. 2005. View Article : Google Scholar : PubMed/NCBI
15	Liu JR, Wang Y, Zuo LF, Li FL, Wang Y and Liu JL: Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma. Ai Zheng. 26:458–462. 2007.PubMed/NCBI
16	Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
17	Senft C, Priester M, Polacin M, Schröder K, Seifert V, Kögel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 101:393–403. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005. View Article : Google Scholar : PubMed/NCBI
19	Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:17511996.
20	Tanaka T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Shiozaki M, Naganawa Y, Fujii Y and Takeyama H: Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res. 29:832010. View Article : Google Scholar : PubMed/NCBI
21	Rinderknecht M and Detmar M: Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 216:347–354. 2008. View Article : Google Scholar
22	Han FH, Li HM, Zheng DH, He YL and Zhan WH: The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol. 36:1172–1179. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ and Koh GY: Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer. 10:362011. View Article : Google Scholar : PubMed/NCBI
24	Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K and Sueishi K: Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol. 175:1709–1721. 2009. View Article : Google Scholar
25	Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W and Chayama K: Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res. 14:7205–7214. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bednarek W, Wertel I and Kotarski J: Lymphangiogenesis in cancerous tumours. Ginekol Pol. 79:625–629. 2008.(In Polish).
27	Saharinen P, Tammela T, Karkkainen MJ and Alitalo K: Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25:387–395. 2004. View Article : Google Scholar : PubMed/NCBI
28	Park GS, Joo YE, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of PTEN and its correlation with angiogenesis in gastric carcinoma. Korean J Gastroenterol. 46:196–203. 2005.PubMed/NCBI
29	Zhao M, Liu F, Wang JY, Zhang WY, Gao FH and Jiang B: Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer. Zhonghua Yi Xue Za Zhi. 91:375–381. 2011.(In Chinese).